Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $2.2 million.

  • Seres Therapeutics' Other Accumulated Expenses fell 77.38% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 77.38%. This contributed to the annual value of $2.2 million for FY2024, which is 21.97% down from last year.
  • Seres Therapeutics' Other Accumulated Expenses amounted to $2.2 million in FY2024, which was down 21.97% from $2.8 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Other Accumulated Expenses registered a high of $3.6 million during FY2022, and its lowest value of $1.2 million during FY2020.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $2.8 million (2023), whereas its average is $2.9 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 215.09% in 2021, then fell by 23.93% in 2023.
  • Yearly analysis of 5 years shows Seres Therapeutics' Other Accumulated Expenses stood at $1.2 million in 2020, then skyrocketed by 215.09% to $3.6 million in 2021, then rose by 0.30% to $3.6 million in 2022, then decreased by 23.93% to $2.8 million in 2023, then decreased by 21.97% to $2.2 million in 2024.